首页> 外文期刊>Nature reviews neuroscience >Treatment of juxta-anastomotic stenoses for failing distal radiocephalic arteriovenous fistulas: Drug-coated balloons versus angioplasty
【24h】

Treatment of juxta-anastomotic stenoses for failing distal radiocephalic arteriovenous fistulas: Drug-coated balloons versus angioplasty

机译:用于远端射孔动静脉瘘的Juxta吻合狭窄的处理:药物涂层气球与血管成形术

获取原文
获取原文并翻译 | 示例
           

摘要

The aim of our study is to report the results of two types (type A, type B) paclitaxel drug-coated balloon compared with standard percutaneous transluminal angioplasty in the treatment of juxta-anastomotic stenoses of mature but failing distal radiocephalic hemodialysis arteriovenous fistulas. Two groups of 26 and 44 patients treated with two different drug-coated balloon are compared with a control group of 86 treated with standard percutaneous transluminal angioplasty. A color Doppler ultrasound was performed to evaluate stenosis and for treatment planning. We assess primary patency, defined as the absence of dysfunction of the arteriovenous fistulas, patent lesion or residual stenosis 30% and no need for further reintervention of target lesion. Primary patency and secondary patency are evaluated after 12 months with color Doppler ultrasound for the whole arteriovenous fistulas, defined as absolute (absolute primary patency, absolute secondary patency) and target lesion. Postprocedural technical and clinical success was 100%. After 12 months, absolute primary patency is 81.8% for type A, 84.1% type B, and 54.7% for standard percutaneous transluminal angioplasty; target lesion primary patency is 92% type A, 86.4% type B, and 62.8% standard percutaneous transluminal angioplasty; absolute secondary patency is 95.4% type A, 95.5% type B, and 80.7% standard percutaneous transluminal angioplasty; target lesion secondary patency is 100% type A, 97.7% type B, and 80.7% standard percutaneous transluminal angioplasty. All the patients treated with drug-coated balloon (type A + type B) have an absolute primary patency of 83.3%, a target lesion primary patency of 87.9%, an absolute secondary patency of 95.5%, and a target lesion secondary patency of 98.4%. Our study confirms that the use of drug-coated balloon, indiscriminately among different brands, improves primary patency with statistically significant difference in comparison with standard percutaneous transluminal angioplasty and decreases reintervention of target lesion in juxta-anastomotic stenoses of failing distal arteriovenous fistulas maintaining the radiocephalic fistula as long as possible.
机译:我们的研究目的是报告两种类型(A型,B型)紫杉醇药物涂层球囊的结果,与标准经皮腔内血管成形术相比,治疗成熟的JUXTA-ANSTOMIC狭窄,但失效远端射孔血液透析动静脉瘘。将两组26和44名用两种不同的药物涂覆的球囊治疗的患者与用标准经皮腔内血管成形术治疗的86个对照组进行比较。进行彩色多普勒超声,以评估狭窄和治疗计划。我们评估初级通畅,定义为缺乏动静脉瘘的功能障碍,专利病变或残余狭窄& 30%,不需要进一步重复目标病变。在整个动静脉瘘的彩色多普勒超声中评价初级通畅和二次通净度在12个月后评价,定义为绝对(绝对初级通畅,绝对的二级通用)和靶病变。后期技术和临床成功为100%。 12个月后,A型,84.1%型B的绝对初级通畅是81.8%,标准经皮腔内血管成形术的54.7%;靶病变初级通畅是92%A,86.4%B型,62.8%标准经皮腔内血管成形术;绝对二级通用是95.4%A,95.5%B型,和80.7%的经皮腔内血管成形术;靶位病变二次通用是100%A,97.7%B型,和80.7%的经皮腔内血管成形术。所有用药物涂层球囊(A型+型B)治疗的患者的绝对初级通用量为83.3%,靶病变初级通用率为87.9%,绝对的二次通用高达95.5%,目标病变二次通用高达98.4 %。我们的研究证实,在不同品牌中使用药物涂层气球,在不同品牌中,与标准经皮腔内血管成形术相比,在统计学上显着差异,并降低了在保持射射的远端动脉瘘中的Juxta-Anastiocit狭窄中的目标病变的重新携带瘘管尽可能长。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号